Moderna said Wednesday (Jan. 13) it expects data from its COVID-19 vaccine trial in children ages 2 to 5 in March.
“If the data is supportive and subject to consultation with regulatory authorities, Moderna may then proceed with registrations for children ages 2-5,” the company said.
Moderna’s vaccine, based on the messenger RNA platform, already has authorizations in Europe, the UK, Australia and Canada for adolescents aged 12 to 17 and has applications for children aged 6 to 11.
In the United States, the vaccine has been approved by the Food and Drug Administration as a primary two-dose schedule and as a booster dose for adults 18 years of age and older. However, the company has yet to get an authorization from the regulator to use its vaccine in children.